Moody National Bank Trust Division Sells 1,254 Shares of Eli Lilly and Company (NYSE:LLY)

Moody National Bank Trust Division lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 9.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,872 shares of the company’s stock after selling 1,254 shares during the quarter. Eli Lilly and Company accounts for about 1.0% of Moody National Bank Trust Division’s investment portfolio, making the stock its 17th biggest position. Moody National Bank Trust Division’s holdings in Eli Lilly and Company were worth $9,165,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Wedmont Private Capital increased its position in shares of Eli Lilly and Company by 8.8% during the 4th quarter. Wedmont Private Capital now owns 14,149 shares of the company’s stock worth $11,318,000 after purchasing an additional 1,147 shares in the last quarter. Talbot Financial LLC increased its holdings in shares of Eli Lilly and Company by 24.6% during the fourth quarter. Talbot Financial LLC now owns 21,276 shares of the company’s stock worth $16,425,000 after buying an additional 4,199 shares in the last quarter. Asset Allocation & Management Company LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $262,000. Cardano Risk Management B.V. boosted its holdings in shares of Eli Lilly and Company by 1.0% in the 4th quarter. Cardano Risk Management B.V. now owns 218,515 shares of the company’s stock worth $168,694,000 after acquiring an additional 2,143 shares in the last quarter. Finally, Kieckhefer Group LLC bought a new position in Eli Lilly and Company in the 4th quarter valued at $193,000. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $0.41 during midday trading on Monday, reaching $799.49. The company’s stock had a trading volume of 1,899,165 shares, compared to its average volume of 2,931,915. The company has a market cap of $758.97 billion, a P/E ratio of 86.43, a P/E/G ratio of 2.99 and a beta of 0.41. Eli Lilly and Company has a fifty-two week low of $612.70 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The business’s 50 day moving average price is $786.08 and its two-hundred day moving average price is $859.41.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. The business’s revenue was up 20.4% compared to the same quarter last year. On average, analysts forecast that Eli Lilly and Company will post 13.18 EPS for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has authorized a share repurchase program on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to buy up to 2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.75%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 64.86%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on LLY shares. Wolfe Research initiated coverage on Eli Lilly and Company in a report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price objective on the stock. Barclays reduced their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Bank of America reissued a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,002.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.